EpiCept Corporation to Present at the 15th BIO CEO & Investor Conference

Wed Feb 6, 2013 7:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130207:nBw066774a

TARRYTOWN, N.Y.--(Business Wire)--
Regulatory News: 

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced
today that Robert W. Cook, Interim President and Chief Executive Officer, will
be presenting at the 15th BIO CEO & Investor Conference on Tuesday, February 12,
2013 at 2:30 PM local time at the Waldorf Astoria, Room Park South, in New York,
New York. Mr. Cook will present a company overview. 

An archive of Mr. Cook`s presentation will be available at www.epicept.com
shortly following the presentation. 

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical
products for the treatment of pain and cancer. The Company's pain portfolio
includes AmiKet, a prescription topical analgesic cream in late-stage clinical
development designed to provide effective long-term relief of pain associated
with peripheral neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose IL-2 is intended as remission maintenance therapy in
the treatment of AML for adult patients who are in their first complete
remission. The Company sold all of its rights to Ceplene® in Europe and certain
Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda
AB in June 2012. Ceplene® is licensed to MegaPharm Ltd. to market and sell in
Israel and EpiCept has retained its rights to Ceplene® in all other countries,
including countries in North and South America. The Company has other oncology
drug candidates in clinical development that were discovered using in-house
technology and have been shown to act as vascular disruption agents in a variety
of solid tumors. 

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. You are urged
to consider statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal," or the
negative of those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include statements which
express plans, anticipation, intent, contingency, goals, targets, future
development and are otherwise not statements of historical fact. These
statements are based on our current expectations and are subject to risks and
uncertainties that could cause actual results or developments to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause actual
results or developments to differ materially include: the risk that we may be
unable to complete the proposed merger transaction with Immune Pharmaceuticals,
the risks associated with the adequacy of our existing cash resources and our
ability to continue as a going concern, the risks associated with our ability to
continue to meet our obligations under our existing debt agreements, the risk
that Azixa® will not receive regulatory approval or achieve significant
commercial success, the risk that clinical trials for AmiKet or crolibulinTM
will not be successful, the risk that AmiKet or crolibulinTM will not receive
regulatory approval or achieve significant commercial success, the risk that we
will not be able to find a partner to help conduct the Phase III trials for
AmiKet on attractive terms, a timely basis or at all, the risk that Ceplene®
will not receive regulatory approval or marketing authorization in the United
States or Canada, the risk that Ceplene® will not achieve significant commercial
success, the risk that our other product candidates that appeared promising in
early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later-stage clinical trials, the risk that we will not obtain
approval to market any of our product candidates, the risks associated with
dependence upon key personnel, the risks associated with reliance on
collaborative partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the cost, delays
and uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating losses
since our inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are more fully
discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and
10-K and other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in our filings
which are available at www.sec.gov or at www.epicept.com. You are cautioned not
to place undue reliance on any forward-looking statements, any of which could
turn out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors.

EpiCept Corporation:
Robert W. Cook, (914) 606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, (617) 577-8110
gregory.kelley@fkhealth.com
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss, (310) 691-7100
bvoss@lhai.com

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.